Tirzepatide vs CJC-1295 & Ipamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →CJC-1295 & Ipamorelin
The most popular growth hormone secretagogue combination. CJC-1295 (a GHRH analog) and Ipamorelin (a ghrelin mimetic) work synergistically to stimulate natural growth hormone release with potentially greater effects than either peptide alone.
Full details →Side-by-Side Comparison
| Aspect | Tirzepatide | CJC-1295 & Ipamorelin |
|---|---|---|
| Mechanism | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. | CJC-1295 binds to GHRH receptors to sustain GH signaling and extend the half-life of growth hormone release. Ipamorelin triggers strong GH pulses by binding to ghrelin receptors. Together, they create both sustained and pulsatile GH release patterns that more closely mimic natural physiology. |
| Typical Dosage | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. | CJC-1295 (no DAC/Mod GRF 1-29): 100-300mcg combined with Ipamorelin 200-300mcg, administered 1-3 times daily. Best results when administered fasted or before sleep. |
| Administration | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. | Subcutaneous injection. Often administered before bedtime to enhance natural nighttime GH release, or in the morning fasted. The combination is typically pre-mixed or injected simultaneously. |
| Side Effects | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. | Water retention, tingling in extremities, mild headaches, lightheadedness, or increased hunger. Generally well-tolerated with minimal effect on cortisol or prolactin. |
| Best For |
What They Have in Common
Both Tirzepatide and CJC-1295 & Ipamorelin are commonly used for: